N-(2-(3,4-dimethoxyphenyl)ethyl)-2,2-diphenylacetamide | 30488-64-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-(3,4-dimethoxyphenyl)ethyl)-2,2-diphenylacetamide
• 英文别名: N-[2-(3,4-dimethoxyphenyl)ethyl]-2,2-diphenylacetamide
• CAS: 30488-64-3
• 化学式: C₂₄H₂₅NO₃
• 分子量: 375.467
• InChiKey: ATNUUEWRLXGFSA-UHFFFAOYSA-N

物化性质

• 沸点：
  585.1±50.0 °C(Predicted)
• 密度：
  1.124±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为产物：
  描述：

  2,2-二苯基乙酸 在 4-二甲氨基吡啶 、 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 60.0h， 生成 N-(2-(3,4-dimethoxyphenyl)ethyl)-2,2-diphenylacetamide
  参考文献：
  名称：

  Synthesis and Identification of Small Molecules that Potently Induce Apoptosis in Melanoma Cells through G1 Cell Cycle Arrest

  摘要：

  Late-stage malignant melanoma is a cancer that is refractory to current chemotherapeutic treatments. The average survival time for patients with such a diagnosis is 6 months. In general, the vast majority of anticancer drugs operate through induction of cell cycle arrest and cell death in either the DNA synthesis (S) or mitosis (M) phase of the cell cycle. Unfortunately, the same mechanisms that melanocytes possess to protect cells from DNA damage often confer resistance to drugs that derive their toxicity from S or M phase arrest. Described herein is the synthesis of a combinatorial library of potential proapoptotic agents and the subsequent identification of a class of small molecules (triphenyl methylamides, TPMAs) that arrest the growth of melanoma cells in the G1 phase of the cell cycle. Several of these TPMAs are quite potent inducers of apoptotic death in melanoma cell lines (IC50 similar to 0.5 mu M), and importantly, some TPMAs are comparatively nontoxic to normal cells isolated from the bone marrow of healthy donors. Furthermore, the TPMAs were found to dramatically reduce the level of active nuclear factor kappa-B (NF kappa B) in the cell; NF kappa B is known to be constitutively active in melanoma, and this activity is critical for the proliferation of melanoma cells and their evasion of apoptosis. Compounds that reduce the level of NF kappa B and arrest cells in the G1 phase of the cell cycle can provide insights into the biology of melanoma and may be effective antimelanoma agents.

  DOI：

  10.1021/ja042913p

文献信息

• Structural Optimization of Berberine as a Synergist to Restore Antifungal Activity of Fluconazole against Drug-Resistant<i>Candida albicans</i>
  作者：Hong Liu、Liang Wang、Yan Li、Jiang Liu、Maomao An、Shaolong Zhu、Yongbing Cao、Zhihui Jiang、Mingzhu Zhao、Zhan Cai、Li Dai、Tingjunhong Ni、Wei Liu、Simin Chen、Changqing Wei、Chengxu Zang、Shujuan Tian、Jingyu Yang、Chunfu Wu、Dazhi Zhang、Hua Liu、Yuanying Jiang

  DOI：10.1002/cmdc.201300332

  日期：2014.1

  We have conducted systematic structural modification, deconstruction, and reconstruction of the berberine core with the aim of lowering its cytotoxicity, investigating its pharmacophore, and ultimately, seeking novel synergistic agents to restore the effectiveness of fluconazole against fluconazole‐resistant Candida albicans. A structure–activity relationship study of 95 analogues led us to identify

  我们已经对黄连素核心进行了系统的结构修饰，解构和重建，以降低其小toxic碱的细胞毒性，研究其药效团，并最终寻求新型协同剂以恢复氟康唑对耐氟康唑的白色念珠菌的有效性。通过对95个类似物的构效关系研究，我们确定了N-（2-（苯并[ d ] [1,3]二恶酚-5-基）乙基）-2-（取代的苯基）乙酰胺的新型骨架7 a -升，这表现出在体外协同抗真菌活性的显着水平。化合物7 d（N-（2-（苯并[ d] [1,3]二恶唑-5-基）乙基）-2-（2-氟苯基）乙酰胺）可显着降低氟康唑相对于耐氟康唑的C的MIC 80值，从128.0μgmL -1降至0.5μgmL -1 。白色念珠菌对人脐静脉内皮细胞的毒性比黄连素低得多。
• [EN] COMPOUNDS AND METHODS FOR TREATMENT OF CANCER AND MODULATION OF PROGRAMMED CELL DEATH FOR MELANOMA AND OTHER CANCER CELLS<br/>[FR] COMPOSES ET PROCEDES DE TRAITEMENT DU CANCER ET MODULATION DE LA MORT CELLULAIRE PROGRAMMEE DE MELANOMES ET D'AUTRES CELLULES CANCEREUSES
  申请人：UNIV ALABAMA

  公开号：WO2005044191A3

  公开（公告）日：2005-10-20
• COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS
  申请人：Angiogenex, Inc.

  公开号：EP3079680A2

  公开（公告）日：2016-10-19
• Chemical Inhibitors of Inhibitors of Differentiation
  申请人：CHAUDHARY Jaideep

  公开号：US20090226422A1

  公开（公告）日：2009-09-10

  The present invention provides identification of inhibitors of inhibitors of differentiation (Id) for use in the treatment and prevention of diseases in mammals. The inhibitors of Id are effective alone in the treatment of a variety of cellular proliferative disorders including, but not limited to, diseases such as cancer, arthritis, age-related macular degeneration, psoriasis, neoplasms, angiomas, endometriosis, obesity, age-related macular degeneration, retinopathies, restenosis, scaring, fibrogenesis, fibrosis, cardiac remodeling, pulmonary fibrosis, scleroderma, failure associated with myocardial infarction, keloids, fibroid tumors and stenting. Additionally, these compounds are effective in blocking angiogenesis in tumor development, inducing apoptosis in malignant cells, inhibiting proliferation of cancer cells, increasing the effectiveness of chemotherapeutic agents, regulating transcriptional activity, reducing inflammation, increasing cellular differentiation, modulating ETS domain transcription factors, modulating PAX transcription factors, modulating TCF-ETS domain transcription factors, down regulating RAF-1/MAPK, upregulating JNK signaling pathways, and modulating cellular transformation.
• US8138356B2
  申请人：——

  公开号：US8138356B2

  公开（公告）日：2012-03-20